The Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) are soliciting research applications for the "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)" funding opportunity. This initiative aims to advance the preclinical development of lead candidate vaccines against Mycobacterium tuberculosis (Mtb) to expand the clinical pipeline. The focus is on established lead candidates with existing proof-of-concept data, and projects must include substantive investment from at least one industry participant. The funding opportunity, RFA-AI-25-022, is open to various organizations, including higher education institutions, nonprofits, and for-profit entities, with an anticipated commitment of $4.73 million in FY 2026 for 4-5 awards, each with a maximum budget of $750,000 direct costs per year over five years. Applications must demonstrate a clear product development strategy, including objectives, timelines, and plans for preclinical evaluation and manufacturing, and must not involve clinical trials.